Loading...
Searching Database & Compiling the results...
This process involves analyzing complex genetic data and may take a moment.
PDX model details
| PDX ID | 435.23A |
|---|---|
| Host Strain(and Source) | NSG Source: Monash University |
| Host Strain Immune system Humanized | NO |
| Host Type | Testosterone supplemented |
| Graft Site | Subcutaneous |
| Current Generation (* indicates number of generations grown in Castrate host) |
4 |
| Average PDX Generation Time (days +/- SEM) | 63 ± 9 |
| Tumour preparation | Tumor solid |
| Tumour Characterization Technology | Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin | Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed | Routine QA every 2-3 passages |
| Associated meta data | |
| PDX model availability | Yes (fixed, frozen) |
| Governance restriction for distribution | Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID | 34413304 |
| Markers | 435.23A |
|---|---|
| AR | N |
| PSA | N |
| PSMA | N |
| NE | Y |
| ERG | N |
This table displays curated CNVs
| PDX ID | Gene Symbol | CNV Log2 | CNV Copy | CNV Call | Experiments name | Platform | Reference genome |
|---|---|---|---|---|---|---|---|
| 435.23A | ZFHX3 | -0.922 | 1.056 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.23A | USP28 | -0.926 | 1.053 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.23A | CDKN1B | -0.895 | 1.075 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.23A | BRCA2 | -0.973 | 1.019 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.23A | BRCA2 | -0.790 | 1.157 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.23A | BRCA2 | -0.917 | 1.059 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.23A | RB1 | -1.336 | 0.792 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.23A | MGA | -1.011 | 0.992 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.23A | CDH1 | -1.126 | 0.916 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.23A | PAX6 | -0.983 | 1.012 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.23A | FANCA | -1.160 | 0.895 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.23A | PRPF8 | -1.116 | 0.923 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.23A | TP53 | -1.116 | 0.923 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.23A | ZNRF3 | -0.971 | 1.020 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.23A | APC | -0.771 | 1.172 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.23A | APC | -0.995 | 1.003 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.23A | APC | -0.928 | 1.051 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.23A | TP53 | -28.374 | 5.750e-09 | Homdel | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.23A | FOXA1 | 0.493 | 2.815 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.23A | CTNNB1 | 0.636 | 3.108 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.23A | CTNNB1 | 0.540 | 2.909 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.23A | PIK3CB | 1.289 | 4.888 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.23A | IGF2R | 0.548 | 2.923 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.23A | KMT2C | 0.540 | 2.909 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.23A | CHD7 | 0.825 | 3.543 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.23A | MYC | 0.577 | 2.984 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.23A | FOXA1 | 0.707 | 3.265 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.23A | SETDB1 | 0.537 | 2.901 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.23A | ARID4A | 0.612 | 3.056 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.23A | CUL3 | -0.900 | 1.072 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.23A | CUL3 | -1.086 | 0.942 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.23A | MLH1 | -0.966 | 1.024 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.23A | SMARCAD1 | -0.840 | 1.117 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.23A | CHD1 | -0.928 | 1.051 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.23A | ERBB4 | -0.900 | 1.072 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.23A | SUFU | -1.009 | 0.994 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
Clinical Information
| Sample Number | 435.23A |
|---|---|
| Sample Site | Right posterior temporal lobe |
| Sample source | Autopsy |
| Pathology Tumour Diagnosis | None |
| Gleason Score | None |
| Primary Gleason Score | None |
| Secondary Gleason Score | None |
| Tertiary Gleason Score | None |
| ISUP Grade Group | |
| Tumour Grade | |
| D'Amico Risk Classification | |
| Tumour Volume (in cc) | 0.0 |
| Treatment Prior to Specimen Collection | ADT, carboplatin plus etoposide |
Patient Information
| Patient Number | 435 |
|---|---|
| Sex | Male |
| Diagnosis | Prostate Cancer |
| PSA at diagnosis (ng/mL) | 16.2 |
| Consent to share data | Yes, subject to ethical review |
| Patient Tumour Collection (Current Model) | |
|---|---|
| Tumour sample ID | 435.23A |
| Patient Age (binned in 5 year age groups) | 65-73 |
This table displays curated sequence variants
| PDX ID | Gene Symbol | Total Read Depth | Alternate Frequency | Consequence | Exon | GnomAD AF | CADD PHRED score | ClinVar significance | Platform | Experiments Name | Reference | Library Type | Instrument Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 435.23A | BRCA2 | 183 | 1.0 | Frameshift variant | '11/28 | . | . | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 435.23A | SUPV3L1 | 503 | 0.67 | Missense variant | '13/15 | . | 31 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 435.23A | IRF4 | 337 | 0.5 | Missense variant | '3/9 | 3.66E-05 | 21.5 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 435.23A | NTRK2 | 320 | 0.49 | Missense variant | '10/21 | . | 27.3 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 435.23A | NOTCH2 | 382 | 0.48 | Frameshift variant | '34/34 | . | . | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 435.23A | TSHR | 425 | 0.43 | Missense variant | '11/11 | . | 27.2 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 435.23A | ATAD2B | 241 | 0.43 | Missense variant | '1/28 | . | 25.1 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
No information in Drug dosing Table